BGB-900-105

Recruiting

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Beigene Study ID info

BGB-900-105

ClinicalTrials.gov ID info

EudraCT Number info

AdvanTIG-105

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents